On November 3, 2020 ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC), a biopharmaceutical group specialized in precision medicine, reported the signature of a new multi-year service agreement (DDSA1) with ViraTherapeutics, a subsidiary of Boehringer Ingelheim based in Innsbruck (Austria) and specialized in oncolytic viral immunotherapy (Press release, Oncodesign, NOV 3, 2020, View Source [SID1234569762]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under this agreement, Oncodesign will play a key role for Austrian biotech company ViraTherapeutics, handling the preclinical assessment of its immunotherapy programs, which aim to develop next-generation vesicular stomatitis virus (VSV-GP) variants in immuno-oncology.
This two-year partnership deal falls within Oncodesign’s development strategy of supporting pharmaceutical and biotech companies during the early development stages of their therapeutic innovations under global strategic alliances.
"We are delighted that we will be working together under this agreement with ViraTherapeutics, a leading innovator in the development of oncolytic viral therapies and part of Boehringer Ingelheim. We are thrilled to be playing our part in their various ground-breaking oncology programs", commented Fabrice Viviani, Managing Director and Head of the Oncodesign Services Business Unit.
"We are proud that ViraTherapeutics chose us as a key partner for conducting its oncolytic virus assessments. This partnership once again confirms the relevance and interest of the industry for our DDSA service offering. It is a tremendous encouragement to consolidate our efforts to put in place strategic agreements with innovative biotech companies and leading decision-makers in the pharmaceutical industry, in order to bring new therapeutic solutions to market as fast as possible to improve patient treatments and meet the strong therapeutic demand in oncology and infectious diseases", added Philippe Genne, Chairman, Chief Executive Officer and Founder of Oncodesign.